About this Research Topic
Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Accurate diagnostic imaging is a prerequisite for tailored and personalized treatment approaches in patients with all stages of prostate cancer by (i) providing a good overview of the disease status before, during and after treatment, (ii) enabling accurate segmentation of PCa lesion and (iii) enabling non-invasive tumor characterization using radiomics or artificial intelligence tools.
Prostate Specific Membrane Antigen (PSMA) has been found to be selectively overexpressed in PCa cells and can be traced by radio-labelled peptide ligands in positron emission tomography (PSMA-PET). First studies suggested excellent diagnostic accuracy and a major impact on therapeutic approaches for PSMA-PET in newly diagnosed, recurrent or metastatic prostate cancer patients.
The goal of this Research Topic is, thus, to concentrate excellent and multidisciplinary scientific contributions on the growing evidence of integrating PSMA-PET imaging in personalized prostate cancer treatment concepts including radiotherapy, surgery, focal therapies, systemic drugs and radioligands. We welcome authors from all disciplines involved in this topic to submit Original Research, (Systematic) Reviews, and Case Reports from clinical and preclinical standpoints that handle PSMA-PET imaging for prostate cancer patients from the diagnostic or therapeutic perspective. Economic analysis, cost effectiveness studies, comparative effectiveness studies, and health services research-related projects are also welcome.
This collection aims to focuses on, but is not limited to, the following themes:
1. Advanced treatment concepts based on PSMA-PET information
2. Treatment monitoring using PSMA-PET images
3. PSMA-PET for the accurate detection and delineation of prostate cancer
4. PSMA-PET guided biopsies or focal therapy approaches
5. PSMA radioguided surgery
6. Economic analyses including cost effectiveness studies and health services research-related projects on PSMA-PET
7. Using PSMA-PET as a biomarker for risk prediction and non-invasive prostate cancer tissue characterization
Prostate Specific Membrane Antigen (PSMA) has been found to be selectively overexpressed in PCa cells and can be traced by radio-labelled peptide ligands in positron emission tomography (PSMA-PET). First studies suggested excellent diagnostic accuracy and a major impact on therapeutic approaches for PSMA-PET in newly diagnosed, recurrent or metastatic prostate cancer patients.
The goal of this Research Topic is, thus, to concentrate excellent and multidisciplinary scientific contributions on the growing evidence of integrating PSMA-PET imaging in personalized prostate cancer treatment concepts including radiotherapy, surgery, focal therapies, systemic drugs and radioligands. We welcome authors from all disciplines involved in this topic to submit Original Research, (Systematic) Reviews, and Case Reports from clinical and preclinical standpoints that handle PSMA-PET imaging for prostate cancer patients from the diagnostic or therapeutic perspective. Economic analysis, cost effectiveness studies, comparative effectiveness studies, and health services research-related projects are also welcome.
This collection aims to focuses on, but is not limited to, the following themes:
1. Advanced treatment concepts based on PSMA-PET information
2. Treatment monitoring using PSMA-PET images
3. PSMA-PET for the accurate detection and delineation of prostate cancer
4. PSMA-PET guided biopsies or focal therapy approaches
5. PSMA radioguided surgery
6. Economic analyses including cost effectiveness studies and health services research-related projects on PSMA-PET
7. Using PSMA-PET as a biomarker for risk prediction and non-invasive prostate cancer tissue characterization
Keywords: PSMA-PET, Prostate Cancer, Staging, Focal Therapy, Theranostics
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
